AU2013245675B2 - Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent - Google Patents

Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent Download PDF

Info

Publication number
AU2013245675B2
AU2013245675B2 AU2013245675A AU2013245675A AU2013245675B2 AU 2013245675 B2 AU2013245675 B2 AU 2013245675B2 AU 2013245675 A AU2013245675 A AU 2013245675A AU 2013245675 A AU2013245675 A AU 2013245675A AU 2013245675 B2 AU2013245675 B2 AU 2013245675B2
Authority
AU
Australia
Prior art keywords
day
colchicine
gout
arhalofenate
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013245675A
Other languages
English (en)
Other versions
AU2013245675A1 (en
Inventor
Brian Edward LAVAN
Charles A. Mcwherter
Brian K. Roberts
Gopal Chandra SAHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diatex Inc
CymaBay Therapeutics Inc
Original Assignee
Diatex Inc
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatex Inc, CymaBay Therapeutics Inc filed Critical Diatex Inc
Publication of AU2013245675A1 publication Critical patent/AU2013245675A1/en
Application granted granted Critical
Publication of AU2013245675B2 publication Critical patent/AU2013245675B2/en
Assigned to DIATEX, INC., CYMABAY THERAPEUTICS, INC. reassignment DIATEX, INC. Request for Assignment Assignors: CYMABAY THERAPEUTICS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013245675A 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent Ceased AU2013245675B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624186P 2012-04-13 2012-04-13
US61/624,186 2012-04-13
PCT/US2013/036474 WO2013155478A1 (en) 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Publications (2)

Publication Number Publication Date
AU2013245675A1 AU2013245675A1 (en) 2014-10-30
AU2013245675B2 true AU2013245675B2 (en) 2017-02-09

Family

ID=49325641

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013245675A Ceased AU2013245675B2 (en) 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Country Status (15)

Country Link
US (1) US20130274331A1 (enExample)
EP (1) EP2836209A4 (enExample)
JP (1) JP2015512948A (enExample)
KR (1) KR20150002799A (enExample)
CN (1) CN104602686A (enExample)
AU (1) AU2013245675B2 (enExample)
CA (1) CA2870014A1 (enExample)
CL (1) CL2014002728A1 (enExample)
EA (1) EA028495B1 (enExample)
HK (1) HK1204913A1 (enExample)
IL (1) IL235154A0 (enExample)
MX (1) MX2014012376A (enExample)
PH (1) PH12014502282A1 (enExample)
SG (1) SG11201406495UA (enExample)
WO (1) WO2013155478A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503440UA (en) 2012-11-02 2015-06-29 Heart Care Western Australia Pty Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
JP7850976B2 (ja) * 2021-08-31 2026-04-24 国立大学法人広島大学 体液サンプリング容器

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151695A1 (en) * 2008-03-13 2009-12-17 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
CA2718062A1 (en) * 2008-03-14 2009-09-17 Intelliherb, Llc Licorice lollipop that inhibits dental caries formation
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
MX357510B (es) * 2011-11-04 2018-07-12 Cymabay Therapeutics Inc Metodos para tratar ataques de gota.
BR112014010693A2 (pt) * 2011-11-04 2020-11-10 Cymabay Therapeutics, Inc. uso de um composto para a preparação de uma composição farmacêutica para o tratamento de gota em subpopulações de pacientes
WO2013066349A1 (en) * 2011-11-04 2013-05-10 Metabolex, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151695A1 (en) * 2008-03-13 2009-12-17 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOPAL C SAHA et al Arthritis and Rheumatism, Vol. 63, No. 10, Supp. , pageS1014. November 2011. *

Also Published As

Publication number Publication date
CN104602686A (zh) 2015-05-06
AU2013245675A1 (en) 2014-10-30
EA201491870A1 (ru) 2015-03-31
EA028495B1 (ru) 2017-11-30
JP2015512948A (ja) 2015-04-30
WO2013155478A1 (en) 2013-10-17
US20130274331A1 (en) 2013-10-17
PH12014502282A1 (en) 2014-12-15
EP2836209A4 (en) 2015-11-25
IL235154A0 (en) 2014-12-31
KR20150002799A (ko) 2015-01-07
SG11201406495UA (en) 2014-11-27
CA2870014A1 (en) 2013-10-17
HK1204913A1 (en) 2015-12-11
MX2014012376A (es) 2015-06-05
CL2014002728A1 (es) 2015-06-19
EP2836209A1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
US10137112B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
JP6008974B2 (ja) 痛風発赤の治療方法
AU2011380507B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
AU2013245675A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations
JP6192142B2 (ja) 痛風発赤の治療方法
US20230210792A1 (en) Use of a combination of colchicine and a cxcr-2 inhibitors for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYMABAY THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): CYMABAY THERAPEUTICS, INC.

Owner name: DIATEX, INC.

Free format text: FORMER APPLICANT(S): CYMABAY THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired